跳至主要内容
临床试验/NCT02582710
NCT02582710Unknown3 期

Impact of an Optimized Formulation of Omega 3 on the Composition of Atheromatous Plaques in Patients Requiring Carotid Endarterectomy

University Hospital, Strasbourg, France1 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2015年5月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
发起方
入组人数
96
试验地点
1
主要终点
Number of participants with treatment-related postive event assessed by the reduction of the concentration of procoagulant microparticles in the atherosclortic plaque

研究概览

简要总结

Determining whether treatment with an optimized formulation of omega 3 for 6 weeks causes a 40% decrease in the average concentration of total microparticles (MPs) in the atheromatous plaque.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
30 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Men or women between 30 and 85 years
  • •Affiliated to a social security scheme
  • •Informed consent signed
  • •Patients to get an endarterectomy carotid stenosis> 70% asymptomatic is
  • •Women of childbearing potential (negative pregnancy test), effective contraception for the duration of the study

排除标准

  • •Inability to give informed information about the study (subject in emergencies, difficulty of understanding ...)
  • •Patient treated by OMACOR®
  • •Patients on oral anticoagulant (AVK, apixaban, dabigatran, rivaroxaban)
  • •Daily consumption of fish oil (medical food with fish oil (omega 3))
  • •Carotid Restenosis
  • •Pregnancy (positive pregnancy test) and lactation
  • •Hypersensitivity to fish
  • •Allergy to fish
  • •Subject under judicial protection
  • •Subjects under guardianship or curatorship

研究组 & 干预措施

VASCAZEN

Experimental

Patients treated with Vascazen

干预措施: VASCAZEN (Dietary Supplement)

Placebo

Placebo Comparator

Patients treated with a placebo

干预措施: PLACEBO (Dietary Supplement)

结局指标

主要结局

Number of participants with treatment-related postive event assessed by the reduction of the concentration of procoagulant microparticles in the atherosclortic plaque

时间窗: an average of 1 to 6 months after the carotid endarterectomy

Microparticle concentration measured by captured-based prothrombinase assay

次要结局

  • Number of participants with treatment-related modification of the content of the plaque assessed by protein biomarkers of the plaque instability and thrombogenicity, and by the identification of the cell origin of the procoagulant microparticles(an average of 1 to 6 months after the carotid endarterectomy)

研究者

发起方
University Hospital, Strasbourg, France
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验